Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024
26 Abril 2024 - 5:16AM
Novo Nordisk A/S – Total number of voting rights and share capital
in Novo Nordisk A/S as of 26 April 2024
Bagsværd, Denmark, 26 April 2024 – In
accordance with Section 32 of the Danish Capital Markets Act, Novo
Nordisk A/S is required to publish the total number of voting
rights and the size of the share capital in Novo Nordisk A/S as per
the end of a month where changes therein have occurred.
Referring to Company Announcement no 32/2024 dated 24 April
2024, please find below a statement regarding the total number of
voting rights and share capital in Novo Nordisk A/S as per 26 April
2024.
|
|
Number of shares (of DKK 0.10
each) |
Share capital (nominal value, DKK) |
Number of votes1 |
|
A shares |
1,074,872,000 |
107,487,200 |
107,487,200,000 |
|
B shares |
3,390,128,000 |
339,012,800 |
33,901,280,000 |
|
Total |
4,465,000,000 |
446,500,000 |
141,388,480,000 |
1 Each A share of DKK 0.01 carries 10 votes, whereas each B
share of DKK 0.01 carries one vote. Thus, each A share of DKK 0.10
carries 100 votes and each B share of DKK 0.10 (the present
denomination of the company's shares) carries 10 votes. Treasury
shares are included in the table above but voting rights of
treasury shares are suspended at the general meetings of Novo
Nordisk A/S.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in
diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 63,400 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X,
LinkedIn and YouTube.
Contact for further information
|
Media: |
|
| Ambre
James-Brown +45 3079 9289abmo@novonordisk.com |
Liz
Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com |
|
Investors: |
|
| Daniel
Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com |
Jacob
Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com |
| David
Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
Mark
Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com |
| Sina
Meyer +45 3079 6656azey@novonordisk.com |
Frederik
Taylor Pitter +45 3075 8259fptr@novonordisk.com |
Company announcement No 33 / 2024
Novo Nordisk (TG:NOV)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Novo Nordisk (TG:NOV)
Gráfica de Acción Histórica
De May 2023 a May 2024
